SCHEMBL18924892

SCHEMBL18924892

CC(=O)c1cccc(COc2ccc3c(c2)C(=O)CCC3)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 15/20 0.68
▸ MAOA P21397 11/20 0.68
▸ NPC1 O15118 4/20 0.61
▸ RAB9A P51151 4/20 0.61
▸ MRGPRX4 Q96LA9 2/20 0.61
▸ POLB P06746 1/20 0.61
▸ GFER P55789 1/20 0.61
▸ PAX8 Q06710 1/20 0.61
▸ KLF5 Q13887 1/20 0.61
▸ L3MBTL1 Q9Y468 1/20 0.61
▸ SMN1; SMN2 Q16637 3/20 0.57
▸ LMNA P02545 2/20 0.57
▸ GAA P10253 1/20 0.57
▸ HPGD P15428 1/20 0.57
▸ KDM4E B2RXH2 1/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ MAPT P10636 1/20 0.53
▸ MDM2 Q00987 1/20 0.53
▸ KMT2A Q03164 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22480508 0.90 MRGPRX4 (0.76) MAOBMAOANPC1RAB9AMRGPRX4
SCHEMBL3501723 0.81 MAOB (1.00) MAOBMAOANPC1RAB9ASMN1; SMN2
SCHEMBL30067289 0.81 MAOB (1.00) MAOBMAOANPC1RAB9ASMN1; SMN2
SCHEMBL6308414 0.81 MAOB (0.82) MAOBMAOA
SCHEMBL17332116 0.81 MAOA (0.55) MAOBMAOANPC1RAB9APOLB
SCHEMBL18924926 0.79 MAOB (0.61) MAOBMAOANPC1RAB9AMRGPRX4
SCHEMBL7215662 0.79 MAOB (0.94) MAOBMAOANPC1RAB9ASMN1; SMN2
SCHEMBL22481089 0.76 MRGPRX4 (1.00) NPC1RAB9AMRGPRX4POLBGFER
SCHEMBL18159338 0.76 NPC1 (0.53) MAOBMAOANPC1RAB9ASMN1; SMN2
SCHEMBL7222729 0.75 MAOB (0.97) MAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11192875-B2 Processes for preparing antiviral compounds GILEAD PHARMASSET LLC (US) 2021-12-07 — — US disclosed
US-20200392100-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2020-12-17 — — US disclosed
US-20190263771-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2019-08-29 — — US disclosed
US-20180179175-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS GILEAD PHARMASSET LLC 2018-06-28 — — US disclosed
US-9890134-B2 Processes for preparing antiviral compounds GILEAD PHARMASSET LLC (US) 2018-02-13 — — US disclosed
US-20170283390-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2017-10-05 — — US disclosed
US-9670187-B2 Processes for preparing antiviral compounds GILEAD PHARMASSET LLC (US) 2017-06-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11192875-B2 Processes for preparing antiviral compounds MAVS, EIF2AK2, SAMHD1 MAOB 1117/4885MAOA 1588/4885NPC1 867/4885
US-20170283390-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SAMHD1 MAOB 1117/4885MAOA 1588/4885NPC1 867/4885
US-20180179175-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SAMHD1 MAOB 1117/4885MAOA 1588/4885NPC1 867/4885
US-20200392100-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SAMHD1 MAOB 1117/4885MAOA 1588/4885NPC1 867/4885
US-20190263771-A1 PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SAMHD1 MAOB 1117/4885MAOA 1588/4885NPC1 867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback